Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment

Article English OPEN
Kosa, Peter; Ghazali, Danish; Tanigawa, Makoto; Barbour, Chris; Cortese, Irene; Kelley, William; Snyder, Blake; Ohayon, Joan; Fenton, Kaylan; Lehky, Tanya; Wu, Tianxia; Greenwood, Mark; Nair, Govind; Bielekova, Bibiana;
  • Publisher: Frontiers Media S.A.
  • Journal: Frontiers in Neurology,volume 7 (issn: 1664-2295, eissn: 1664-2295)
  • Related identifiers: doi: 10.3389/fneur.2016.00131, doi: 10.3389/fneur.2016.00131/full, pmc: PMC4983704
  • Subject: clinical trial | Neurology. Diseases of the nervous system | outcome measure | outcome measures | multiple sclerosis | Neuroscience | RC346-429 | composite scale | Progressive multiple sclerosis | quantitative MRI | disability scale | progressive MS | clinical trials | Original Research

Therapeutic advance in progressive multiple sclerosis (MS) has been very slow. Based on the transformative role magnetic resonance imaging (MRI) contrast-enhancing lesions had on drug development for relapsing-remitting MS, we consider the lack of sensitive outcomes to ... View more
Share - Bookmark